Adlai Nortye Group Ltd. (ANL) Form 6-K — Oct 28, 2026

$ANLForm 6-KFiled Oct 28, 2026, 6:04 AM ET0001213900-26-113051Original filing

Adlai Nortye Group Ltd. (NASDAQ: ANL) announced that a late-breaking abstract on its lead RAS-pathway program AN4035 was selected for an oral presentation at the 38th EORTC-NCI-AACR (ENA) Symposium in Barcelona, taking place November 18-20, 2026. The presentation, to be delivered by President and Head of R&D Dr. Archie Tse on November 19, will include translational data and EGFR combination data from the ongoing global Phase I study of AN4035.

Key figures

Conference: 38th EORTC-NCI-AACR (ENA) Symposium
Trial Phase: Phase I
Trial Countries: ["Australia","U.S.","China"]
Presentation Date: 2026-11-19

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.